The Importance of Including Underserved Populations in Research.

IF 3.1 Q2 PHARMACOLOGY & PHARMACY
Pharmaceutical Medicine Pub Date : 2025-03-01 Epub Date: 2025-04-01 DOI:10.1007/s40290-025-00562-1
Kayla R Mehl, Stephanie R Morain, Emily A Largent
{"title":"The Importance of Including Underserved Populations in Research.","authors":"Kayla R Mehl, Stephanie R Morain, Emily A Largent","doi":"10.1007/s40290-025-00562-1","DOIUrl":null,"url":null,"abstract":"<p><p>This paper provides an overview of the ethical considerations surrounding the inclusion of underserved populations in later-phase clinical trials. Underserved populations, defined here as those with restricted access to or limited benefits from healthcare, often face systemic, logistical, and social barriers that limit their participation in research. This results in a lack of representation that undermines fairness in research and also hampers the development of effective inclusive healthcare practices. This paper argues that including underserved populations in research is crucial for promoting justice, increasing the generalizability of research findings, and building trust in medical institutions. It differentiates underserved populations from other populations of interest, including vulnerable, minority, and underrepresented groups. It then explores barriers to research participation and targeted solutions for four underserved populations: rural residents, racial and ethnic minorities, low-income individuals, and older adults. Strategies for improving participation include expanding trial sites to accessible locations, lowering financial and logistical barriers, broadening eligibility criteria, and fostering culturally tailored outreach and engagement. While some interventions may apply broadly across groups, effective solutions will often require intersectional and context-specific strategies tailored to each population's unique needs as well as coordinated efforts from multiple stakeholders. While these interventions alone cannot resolve healthcare inequities - as underrepresentation of underserved populations in research is just one contributing factor - their widespread implementation would represent meaningful steps toward advancing health equity.</p>","PeriodicalId":19778,"journal":{"name":"Pharmaceutical Medicine","volume":" ","pages":"59-71"},"PeriodicalIF":3.1000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40290-025-00562-1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/1 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

This paper provides an overview of the ethical considerations surrounding the inclusion of underserved populations in later-phase clinical trials. Underserved populations, defined here as those with restricted access to or limited benefits from healthcare, often face systemic, logistical, and social barriers that limit their participation in research. This results in a lack of representation that undermines fairness in research and also hampers the development of effective inclusive healthcare practices. This paper argues that including underserved populations in research is crucial for promoting justice, increasing the generalizability of research findings, and building trust in medical institutions. It differentiates underserved populations from other populations of interest, including vulnerable, minority, and underrepresented groups. It then explores barriers to research participation and targeted solutions for four underserved populations: rural residents, racial and ethnic minorities, low-income individuals, and older adults. Strategies for improving participation include expanding trial sites to accessible locations, lowering financial and logistical barriers, broadening eligibility criteria, and fostering culturally tailored outreach and engagement. While some interventions may apply broadly across groups, effective solutions will often require intersectional and context-specific strategies tailored to each population's unique needs as well as coordinated efforts from multiple stakeholders. While these interventions alone cannot resolve healthcare inequities - as underrepresentation of underserved populations in research is just one contributing factor - their widespread implementation would represent meaningful steps toward advancing health equity.

在研究中纳入服务不足人群的重要性。
本文概述了在后期临床试验中纳入服务不足人群的伦理考虑。服务不足人群(这里定义为获得医疗保健的机会有限或受益有限的人群)往往面临系统、后勤和社会障碍,限制了他们参与研究。这导致缺乏代表性,破坏了研究的公平性,也阻碍了有效的包容性医疗实践的发展。本文认为,将服务不足的人群纳入研究对于促进公正、增加研究结果的普遍性以及建立对医疗机构的信任至关重要。它将服务不足的人群与其他感兴趣的人群区分开来,包括弱势群体、少数民族和代表性不足的群体。然后,它探讨了参与研究的障碍和针对四种服务不足人群的有针对性的解决方案:农村居民、种族和少数民族、低收入个人和老年人。改善参与的战略包括将试验地点扩大到可到达的地点,降低财政和后勤障碍,扩大资格标准,以及促进有文化针对性的推广和参与。虽然一些干预措施可能广泛适用于各个群体,但有效的解决办法往往需要针对每个群体的独特需求制定交叉和具体情况的战略,并需要多个利益攸关方的协调努力。虽然这些干预措施本身不能解决卫生保健不平等问题——因为研究中得不到充分服务的人群的代表性不足只是一个促成因素——但它们的广泛实施将是促进卫生公平的有意义的步骤。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pharmaceutical Medicine
Pharmaceutical Medicine PHARMACOLOGY & PHARMACY-
CiteScore
5.10
自引率
4.00%
发文量
36
期刊介绍: Pharmaceutical Medicine is a specialist discipline concerned with medical aspects of the discovery, development, evaluation, registration, regulation, monitoring, marketing, distribution and pricing of medicines, drug-device and drug-diagnostic combinations. The Journal disseminates information to support the community of professionals working in these highly inter-related functions. Key areas include translational medicine, clinical trial design, pharmacovigilance, clinical toxicology, drug regulation, clinical pharmacology, biostatistics and pharmacoeconomics. The Journal includes:Overviews of contentious or emerging issues.Comprehensive narrative reviews that provide an authoritative source of information on topical issues.Systematic reviews that collate empirical evidence to answer a specific research question, using explicit, systematic methods as outlined by PRISMA statement.Original research articles reporting the results of well-designed studies with a strong link to wider areas of clinical research.Additional digital features (including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations) can be published with articles; these are designed to increase the visibility, readership and educational value of the journal’s content. In addition, articles published in Pharmaceutical Medicine may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand important medical advances.All manuscripts are subject to peer review by international experts. Letters to the Editor are welcomed and will be considered for publication.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信